Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2021 07:30 ET | Source: Helsinn Healthcare S.A.

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Health Canada Issues...
June 24, 2021 08:30 ET | Source: Helsinn Healthcare S.A.

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...
April 29, 2021 03:00 ET | Source: Helsinn Healthcare S.A.

Helsinn appoints Mary Lynne Hedley to Board of Directors

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
April 29, 2021 03:00 ET | Source: Helsinn Healthcare S.A.

Helsinn appoints Mary Lynne Hedley to Board of Directors

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
April 21, 2021 02:30 ET | Source: Helsinn Healthcare S.A.

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building...
April 13, 2021 08:00 ET | Source: Helsinn Healthcare S.A.

Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV

Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV Lugano, Switzerland, April 13, 2021 – Helsinn,...
March 31, 2021 07:30 ET | Source: Helsinn Healthcare S.A.

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through its Affiliate QED...
March 18, 2021 08:30 ET | Source: Helsinn Healthcare S.A.

Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting

Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
February 18, 2021 08:00 ET | Source: Helsinn Healthcare S.A.

Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety

Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
January 22, 2021 01:39 ET | Source: Helsinn Healthcare S.A.

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media ...